US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Annexin receives approval to start Phase 2 study in U.S.

Annexin Pharmaceuticals has been given the go-ahead by FDA to start the planned phase 2 clinical trial with the drug candidate ANXV in patients with retinal vein occlusion (RVO).   STOCKHOLM (5 April, 2022) - This first study with ANXV in patients aims to investigate safety, tolerability and efficacy related to vision and retinal function of RVO patients. The study is a placebo-controlled, multiple-dose trial involving approximately 20 patients at 6-8 eye clinics in the U.S.  The overall results of the study are expected during the 4th quarter of 2022. RVO is a vascular disease of

Approval of COVID19-study

Maastricht University Hospital receives approvals to start study with Annexin Pharmaceuticals drug candidate, ANXV, in patients with COVID19.STOCKHOLM, SWEDEN (January 19, 2022) – Annexin Pharmaceuticals AB (publ) announces that its collaborators at Maastricht University Hospital, Maastricht, The Netherlands, have received approvals from the Dutch regulatory authority and Hospital committees to start a trial with ANXV (a recombinant human Annexin A5) in hospitalised COVID-19 patients. The study follows upon Annexin Pharmaceutical’s completed Phase 1 trial of ANXV in healthy volunteers.

Last day of trading in paid subscription units (Sw. BTU) and first day of trading for warrants of series TO3

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONGKONG, SWITZERLAND, SINGAPORE, NEW ZEALAND, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFULLast day of trading in BTU (paid subscription units) in Annexin Pharmaceuticals AB ("Annexin" or the “Company") will be Wednesday November 24, 2021 and the stop date at Euroclear for conversion of BTU to ordinary shares and warrants of series TO3 will be Friday November 30, 2021. First day of trading in

Annexin announces outcome of rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONGKONG, SWITZERLAND, SINGAPORE, NEW ZEALAND, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFULAnnexin Pharmaceuticals AB (publ) (“Annexin” or “the Company”) announces today that the rights issue of shares and warrants of series TO3 (“Units”) (the “Rights Issue”) has been completed. 42,011,156 Units, approximately 71.4 per cent of the Rights Issue, were subscribed for by the exercise of unit rights

Initiation of clinical imaging study

Annexin Pharmaceuticals and Collaborators Initiate a Clinical Study in Patients with Retinal Vein Occlusion (RVO) Using Fluorescent Labelled ANXV.STOCKHOLM, SWEDEN (September 29, 2021) – Annexin Pharmaceuticals AB (publ) (“Annexin”) announces that its collaborators have received approval from the Dutch regulatory authority to start an innovative clinical molecular imaging study of Annexin’s fluorescent labelled candidate drug ANXV in patients with venous occlusion in the retina (RVO). The trial is managed by TRACER, a CRO specialized in fast-track clinical imaging trials, and is being

Annexin Pharmaceuticals in collaboration for COVID-19 study

Physicians in the Netherlands plan to start a COVID-19 study with Annexin Pharmaceuticals drug candidate ANXV and have to this end submitted an application to the local authority. Annexin Pharmaceuticals will provide ANXV and has secured funding to take part in the study.A medical research team at the Maastricht University Hospital, The Netherlands has proposed an investigator initiated clinical trial to evaluate the safety and potential effects of ANXV treatment in patients with moderate to severe COVID-19. Previously published findings in COVID-19 patients show that ANXV could dampen

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe